22.84
+0.51(+2.28%)
Currency In USD
| Previous Close | 22.33 |
| Open | 22.29 |
| Day High | 23.46 |
| Day Low | 22.29 |
| 52-Week High | 26.99 |
| 52-Week Low | 12.62 |
| Volume | 4,723 |
| Average Volume | 3,182 |
| Market Cap | 59.78M |
| PE | -7.82 |
| EPS | -2.92 |
| Moving Average 50 Days | 17.35 |
| Moving Average 200 Days | 17.19 |
| Change | 0.51 |
If you invested $1000 in vTv Therapeutics Inc. (VTVT) 10 years ago, it would be worth $83.24 as of September 29, 2025 at a share price of $22.84. Whereas If you bought $1000 worth of vTv Therapeutics Inc. (VTVT) shares 5 years ago, it would be worth $317.22 as of September 29, 2025 at a share price of $22.84.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
vTv Therapeutics Will Participate in INNODIA Symposium at the EASD 61st Annual Meeting
GlobeNewswire Inc.
Sep 15, 2025 12:00 PM GMT
Company to share new independent research on TTP-RA, vTv’s oral RAGE antagonistHIGH POINT, N.C., Sept. 15, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company, today announced that the company will
UPDATE -- vTv Therapeutics to Participate in Upcoming September Investor Conferences
GlobeNewswire Inc.
Sep 03, 2025 8:57 PM GMT
HIGH POINT, N.C., Sept. 03, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin bein
vTv Therapeutics to Participate in Upcoming September Investor Conferences
GlobeNewswire Inc.
Sep 03, 2025 12:00 PM GMT
HIGH POINT, N.C., Sept. 03, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin bein